
Pancreatic Cancer Breakthrough: RevMed's Daraxonrasib Drug Shows Major Survival Gains
Revolution Medicines announced highly positive results from a Phase 3 clinical trial for its drug, daraxonrasib, targeting pancreatic cancer. The trial data showed that daraxonrasib significantly extended overall survival, allowing patients to live an average of 13.2 months, compared to 6.7 months when receiving standard chemotherapy. The drug functions by targeting RAS mutations, which are responsible for tumor growth in about 90% of pancreatic cancer cases. The company plans to seek FDA approval for second-line treatment and highlighted the drug's potential to usher in a new era of targeted therapies for this aggressive cancer. Following the announcement, the company's stock saw a jump of over 30%.






















